Enhanced expression of EGF receptor in a model of salt-sensitive hypertension

American Journal of Physiology - Renal Physiology

Volumn 289, Issue 2 58-2, 2005, Pages

  Ying, Wei Zhong ^a   Sanders, Paul W ^a,b,c,d  

^a University of Alabama at Birmingham   (United States)

^b UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^c BIRMINGHAM VA MEDICAL CENTER   (United States)

^d UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

Author keywords

Chronic kidney disease; Vascular smooth muscle

Indexed keywords

EPIDERMAL GROWTH FACTOR; EPIDERMAL GROWTH FACTOR RECEPTOR; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; POLYCLONAL ANTIBODY; PROTEIN KINASE B;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AORTA; ARTERIOLE; ARTICLE; AUTOPHOSPHORYLATION; CELL HYPERPLASIA; CHRONIC KIDNEY DISEASE; CONTROLLED STUDY; ENZYME ACTIVATION; GENE EXPRESSION; HYPERTENSION; IMMUNOHISTOCHEMISTRY; KIDNEY BLOOD VESSEL; KIDNEY CORTEX; MALE; MITOGENESIS; NONHUMAN; PRIORITY JOURNAL; RAT; RAT STRAIN; RECEPTOR UPREGULATION; SIGNAL TRANSDUCTION; STIMULUS; VASCULAR SMOOTH MUSCLE; VASOCONSTRICTION;

EID: 22344437196     PISSN: 1931857X     EISSN: 15221466     Source Type: Journal    
DOI: 10.1152/ajprenal.00003.2005     Document Type: Article

References (42)

1. Breyer MD, Redha R, and Breyer JA. Segmental distribution of epidermal growth factor binding sites in rabbit nephron. Am J Physiol Renal Fluid Electrolyte Physiol 259: F553-F558, 1990.
2. Brown DM, Provoost AP, Daly MJ, Lander ES, and Jacob HJ. Renal disease susceptibility and hypertension are under independent genetic control in the fawn-hooded rat. Nat Genet 12: 44-51, 1996.
3. Carmines PK, Fallet RW, Che Q, and Fujiwara K. Tyrosine kinase involvement in renal arteriolar constrictor responses to angiotensin II. Hypertension 37: 569-573, 2001.
4. 2+ influx in afferent arterioles. Hypertension 40: 700-706, 2002.
5. Chen PY, Gladish RG, and Sanders PW. Vascular smooth muscle nitric oxide synthase anomalies in Dahl/Rapp salt-sensitive rats. Hypertension 31: 918-924, 1998.
6. Chen PY and Sanders PW. L-Arginine abrogates salt-sensitive hypertension in Dahl/Rapp rats. J Clin Invest 88: 1559-1567, 1991.
7. Chen PY and Sanders PW. Role of nitric oxide synthesis in salt-sensitive hypertension in Dahl/Rapp rats. Hypertension 22: 812-818, 1993.
8. Chen PY, St John PL, Kirk KA, Abrahamson DR, and Sanders PW. Hypertensive nephrosclerosis in the Dahl/Rapp rat. Initial sites of injury and effect of dietary L-arginine administration. Lab Invest 68: 174-184, 1993.
9. Churchill PC, Churchill MC, Bidani AK, Griffin KA, Picken M, Pravenec M, Kren V, St Lezin E, Wang JM, Wang N, and Kurtz TW. Genetic susceptibility to hypertension-induced renal damage in the rat. Evidence based on kidney-specific genome transfer. J Clin Invest 100: 1373-1382, 1997.
10. Churchill PC, Churchill MC, Griffin KA, Picken M, Webb RC, Kurtz TW, and Bidani AK. Increased genetic susceptibility to renal damage in the stroke-prone spontaneously hypertensive rat. Kidney Int 61: 1794-1800, 2002.
11. Coresh J, Wei GL, McQuillan G, Brancati FL, Levey AS, Jones C, and Klag MJ. Prevalence of high blood pressure and elevated serum creatinine level in the United States: findings from the third National Health and Nutrition Examination Survey (1988-1994). Arch Intern Med 161: 1207-1216, 2001.
12. Cowley AW Jr, Roman RJ, Kaldunski ML, Dumas P, Dickhout JG, Greene AS, and Jacob HJ. Brown Norway chromosome 13 confers protection from high salt to consomic Dahl S rat. Hypertension 37: 456-461, 2001.
13. Davies SP, Reddy H, Caivano M, and Cohen P. Specificity and mechanism of action of some commonly used protein kinase inhibitors. Biochem J 351: 95-105, 2000.
14. Eguchi S, Dempsey PJ, Frank GD, Motley ED, and Inagami T. Activation of MAPKs by angiotensin II in vascular smooth muscle cells. Metalloprotease- dependent EGF receptor activation is required for activation of ERK and p38 MAPK but not for JNK J. Biol Chem 276: 7957-7962, 2001.
15. Flamant M, Tharaux PL, Placier S, Henrion D, Coffman T, Chatziantoniou C, and Dussaule JC. Epidermal growth factor receptor trans-activation mediates the tonic and fibrogenic effects of endothelin in the aortic wall of transgenic mice. FASEB J 17: 327-329, 2003.
16. François H, Placier S, Flamant M, Tharaux PL, Chansel D, Dussaule JC, and Chatziantoniou C. Prevention of renal vascular and glomerular fibrosis by epidermal growth factor receptor inhibition. FASEB J 18: 926-928, 2004.
17. Gesualdo L, Di Paolo S, Calabro A, Milani S, Maiorano E, Ranieri E, Pannarale G, and Schena FP. Expression of epidermal growth factor and its receptor in normal and diseased human kidney: an immunohistochemical and in situ hybridization study. Kidney Int 49: 656-665, 1996.
18. Hao L, Du M, Lopez-Campistrous A, and Fernandez-Patron C. Agonist-induced activation of matrix metalloproteinase-7 promotes vasoconstriction through the epidermal growth factor-receptor pathway. Circ Res 94: 68-76, 2004.
19. Harris RC. Response of rat inner medullary collecting duct to epidermal growth factor. Am J Physiol Renal Fluid Electrolyte Physiol 256: F1117-F1124, 1989.
20. Harris RC and Daniel TO. Epidermal growth factor binding, stimulation of phosphorylation, and inhibition of gluconeogenesis in rat proximal tubule. J Cell Physiol 139: 383-391, 1989.
21. Jorissen RN, Walker F, Pouliot N, Garrett TP, Ward CW, and Burgess AW. Epidermal growth factor receptor: mechanisms of activation and signalling. Exp Cell Res 284: 31-53, 2003.
22. Kagiyama S, Eguchi S, Frank GD, Inagami T, Zhang YC, and Phillips MI. Angiotensin II-induced cardiac hypertrophy and hypertension are attenuated by epidermal growth factor receptor antisense. Circulation 106: 909-912, 2002.
23. Perry HM Jr, Miller JP, Fornoff JR, Baty JD, Sambhi MP, Rutan G, Moskowitz DW, and Carmody SE. Early predictors of 15-year end-stage renal disease in hypertensive patients. Hypertension 25: 587-594, 1995.
24. Provoost AP, Shiozawa M, Van Dokkum RP, and Jacob HJ. Transfer of the Rf-1 region from FHH onto the ACI background increases susceptibility to renal impairment. Physiol Genomics 8: 123-129, 2002.
25. Rostand SG, Kirk KA, Rutsky EA, and Pate BA. Racial differences in the incidence of end stage renal disease. N Engl J Med 306: 1276-1279, 1982.
26. Saltis J, Thomas AC, Agrotis A, Campbell JH, Campbell GR, and Bobik A. Expression of growth factor receptors in arterial smooth muscle cells. Dependency on cell phenotype and serum factors. Atherosclerosis 118: 77-87, 1995.
27. Sanders PW and Wang PX. Activation of the Fas/Fas ligand pathway in hypertensive renal disease in Dahl/Rapp rats. BMC Nephrol 3: 1, 2002.
28. Schlessinger J. Cell signaling by receptor tyrosine kinases. Cell 103: 211-225, 2000.
29. Schlessinger J. Common and distinct elements in cellular signaling via EGF and FGF receptors. Science 306: 1506-1507, 2004.
30. Swaminathan N and Sambhi MP. Induction of high affinity epidermal growth factor binding in the aorta of Dahl hypertensive rats fed with high salt diet. Hypertens Res 19: 65-68, 1996.
31. US Renal Data System. USRDS 2001 Annual Data Report: Atlas of End-Stage Renal Disease in the United States. Bethesda. MD: National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, 2001.
32. Uchiyama-Tanaka Y, Matsubara H, Mori Y, Kosaki A, Kishimoto N, Amano K, Higashiyama S, and Iwasaka T. Involvement of HB-EGF and EGF receptor transactivation in TGF-β-mediated fibronectin expression in mesangial cells. Kidney Int 62: 799-808, 2002.
33. Ushio-Fukai M, Griendling KK, Becker PL, Hilenski L, Halleran S, and Alexander RW. Epidermal growth factor receptor transactivation by angiotensin II requires reactive oxygen species in vascular smooth muscle cells. Arterioscler Thromb Vasc Biol 21: 489-495, 2001.
34. Wang PX and Sanders PW. Mechanism of hypertensive nephropathy in the Dahl/Rapp rat: a primary disorder of vascular smooth muscle. Am J Physiol Renal Physiol 288: F236-F242, 2005.
35. Ying WZ and Sanders PW. Cytochrome c mediates apoptosis in hypertensive nephrosclerosis in Dahl/Rapp rats. Kidney Int 59: 662-668, 2001.
36. 1. Am J Physiol Renal Physiol 275: F18-F24, 1998.
37. 1 in rat aortic endothelium. Am J Physiol Heart Circ Physiol 277: H1293-H1298, 1999.
38. Ying WZ and Sanders PW. Dietary salt modulates renal production of transforming growth factor-β in rats. Am J Physiol Renal Physiol 274: F635-F641, 1998.
39. Ying WZ and Sanders PW. Increased dietary salt activates rat aortic endothelium. Hypertension 39: 239-244, 2002.
40. Ying WZ and Sanders PW. Accelerated ubiquitination and proteasome degradation of a genetic variant of inducible nitric oxide synthase. Biochem J 376: 789-794, 2003.
41. Ying WZ, Wang PX, and Sanders PW. Induction of apoptosis during development of hypertensive nephrosclerosis. Kidney Int 58: 2007-2017, 2000.
42. Ying WZ, Xia H, and Sanders PW. A nitric oxide synthase (NOS2) mutation in Dahl/Rapp rats decreases enzyme stability. Circ Res 89: 317-322, 2001.